ALPS Jumps 15%

Alps Group Inc. 75 in after-hours trading on Tuesday after the Malaysia-headquartered biotech announced a research collaboration targeting patient-derived organoid technology for personalized cancer care. Alps Group announced the agreement before the market opened on Tuesday. The deal is with Dr.

Kong Wai Mun, Executive Director of Axiocell Biotech, positioning ALPS to build Malaysia’s first clinically validated PDO platform, growing 3D “mini-tumors” from a patient’s own cancer tissue to predict treatment response before therapy begins. 5 million by 2036, according to Future Market Insights. 5% Compound Annual Growth Rate. 8% diagnosed at advanced stages.

Regulatory Path Defined CEO Dr. ” Regulatory steps include ethics approval from Malaysia’s Medical Research Ethics Committee and registration with the Medical Device Authority ahead of commercialization. 42 million. 56.

79. 47%. The small-cap stock is currently trading near the bottom of its 52-week range. ALPS’s sharp decline and weak positioning suggest ongoing pressure may continue, highlighting higher risk and the need for clearer turnaround signals before sentiment improves.

77%, Benzinga’s Edge Stock Rankings indicate that ALPS has a negative price trend across all time frames. com Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published editors. Read Also: Megan Holdings (MGN) Stock Is Trending Overnight — Here's Why It Spiked 92% In After-Hours Session